Analyst Research Report Snapshot


Dr. Reddys Laboratories Limited




MarketLine (a Datamonitor Company)


08 Apr 2014





Companies referenced:


Available for Immediate Download

Dr. Reddy's Laboratories Limited - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Dr. Reddy's Laboratories Limited required for business and competitor intelligence needs - A study of the major internal and external factors affecting Dr. Reddy's Laboratories Limited in the form of a SWOT analysis - An in-depth view of the business model of Dr. Reddy's Laboratories Limited including a breakdown and examination of key business segments - Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Dr. Reddy's Laboratories Limited - Intelligence on Dr. Reddy's Laboratories Limitednv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Dr. Reddy's Laboratories Limited, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Dr. Reddy's Laboratories (DRL or 'the company') is an India-based integrated global pharmaceutical company. DRL is engaged in the production and distribution of generics, finished dosage forms, active pharmaceutical ingredients and intermediates. It is also involved in the discovery of new chemical entities for subsequent commercialization and out-licensing. The company primarily operates in India, the US, Russia and Europe. It is headquartered in Hyderabad, India, and employed 15,200 people as of March 31, 2012. The company recorded revenues of INR96,737 million ($2,002.5 million*) during the financial year ended March 2012 (FY2012), an increase of 29.5% over FY2011. The operating profit of the company was INR18,252 million ($377.8 million*) in FY2012, an increase of 44.5% over FY2011. The net profit was INR14,262 million ($295.2 million*) in FY2012, an increase of 29.2% over FY2011. *Calculated using a constant conversion rate of INR1 = $0.0207 during the financial year ended March 31, 2012. Reasons to Purchase: - Gain understanding of Dr. Reddy's Laboratories Limited and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Dr. Reddy's Laboratories Limited as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Dr. Reddy's Laboratories Limited’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.